| __timestamp | Axsome Therapeutics, Inc. | Catalent, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 334800000 |
| Thursday, January 1, 2015 | 2419289 | 337300000 |
| Friday, January 1, 2016 | 6343648 | 358100000 |
| Sunday, January 1, 2017 | 7206691 | 402600000 |
| Monday, January 1, 2018 | 9351522 | 462600000 |
| Tuesday, January 1, 2019 | 13598030 | 512000000 |
| Wednesday, January 1, 2020 | 28896749 | 577900000 |
| Friday, January 1, 2021 | 66646205 | 687000000 |
| Saturday, January 1, 2022 | 159253661 | 844000000 |
| Sunday, January 1, 2023 | 323123000 | 831000000 |
| Monday, January 1, 2024 | 411359000 | 935000000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Catalent, Inc. and Axsome Therapeutics, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Catalent consistently maintained higher SG&A expenses, peaking at approximately $935 million in 2024. In contrast, Axsome's expenses surged from a modest $1.4 million in 2014 to $323 million in 2023, reflecting its rapid growth trajectory.
Catalent's expenses grew by about 180% over the decade, while Axsome's skyrocketed by over 23,000%, highlighting its aggressive expansion strategy. However, the absence of 2024 data for Axsome suggests a potential gap in reporting or a strategic shift. This comparison underscores the diverse approaches companies take in managing operational costs, with Catalent focusing on steady growth and Axsome on rapid scaling.
Comparing SG&A Expenses: AbbVie Inc. vs Catalent, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Axsome Therapeutics, Inc.
Breaking Down SG&A Expenses: Genmab A/S vs Catalent, Inc.
Selling, General, and Administrative Costs: Catalent, Inc. vs Walgreens Boots Alliance, Inc.
Breaking Down SG&A Expenses: Catalent, Inc. vs Veracyte, Inc.
Cost Management Insights: SG&A Expenses for Catalent, Inc. and Travere Therapeutics, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Axsome Therapeutics, Inc. Trends and Insights
Axsome Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and Amicus Therapeutics, Inc.
Axsome Therapeutics, Inc. and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Axsome Therapeutics, Inc. vs Dynavax Technologies Corporation Trends and Insights
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Evotec SE